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cense.Abstract Objective: Colonic carcinoma is one of the most common cancers worldwide. Recently,
the possible involvement of claudin-1, one of the major tight junction proteins, in the process of
tumorigenesis has been suggested. Also, claudin-1 has emerged as a potential prognostic factor
in different types of tumors. The aim of this study was to detect caludin-1 expression in colonic car-
cinoma and to correlate its expression with clinicopathological variables in an attempt to delineate
its role as a potential new prognostic marker.
Material and methods: Immunohistochemical expression of claudin-1 was assessed in 50 Egyptian
patients with colonic adenocarcinoma. The predictive performance of claudin-1 expression was sta-
tistically evaluated.
Results: Decreased claudin-1 expression was found in 62% of colonic adenocarcinoma cases while
similar expression was found in 38%. Statistical analysis showed a statistically signiﬁcant inverse
correlation between claudin-1 expression and tumor grade, depth of invasion, lymph node involve-
ment, and tumor stage. Regression analysis showed that claudin-1 decreased expression signiﬁ-
cantly predicts that the tumor is of a high grade, high stage, and is associated with lymph nodegalaa St. Victoria, Alexandria,
o.com (E. Abdelzaher).
Institute, Cairo University.
.
University.
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124 E. Abdelzaher et al.involvement. ROC curve analysis showed that claudin-1 had a sensitivity of 88.24% and a speciﬁc-
ity of 81.25% for the prediction of tumor stage and a sensitivity of 73.33% and a speciﬁcity of
82.86% for the prediction of lymph node involvement.
Conclusions: Claudin-1 decreased expression in colonic carcinoma contributes to tumor dedifferen-
tiation, invasion and metastasis. Claudin-1 expression could be used as a predictor of colonic car-
cinoma stage and lymph node status with a high sensitivity and speciﬁcity.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Colonic carcinoma is the fourth most common cancer world-
wide with an estimated one million new cases and a half million
deaths each year [1]. In Africa colonic carcinoma accounts for
just 2.5% of all cancers compared to 9.5% in developed coun-
tries [2]. According to the Egyptian National Cancer Institute,
colonic carcinoma in Egypt contributes 6.5% of all cancers [3].
It is now clear that colonic carcinoma results from a multi-
step accumulation of genetic alterations in proto-oncogenes,
tumor suppressor genes and DNA repair genes [4]. In sporadic
colonic carcinoma, these alterations are acquired, and are
likely to be caused by exogenous and endogenous carcinogens.
In contrast, in cancer syndromes, critical genetic alterations
that predispose to malignancy are inherited [5].
Due to the increasing incidence of colonic carcinoma, sev-
eral studies have been done in an attempt to understand its
pathogenesis and assess the most valuable prognostic factor
[6]. Pathologic staging of colonic carcinoma is the best avail-
able clinicopathologic prognostic marker, however, there is
an urgent need to ﬁnd markers that can stratify patients better
and earlier according to their risk of colonic carcinoma recur-
rence and overall survival [7]. In recent years a large number of
prognostic markers have been suggested for colonic carcinoma
[8–10].
Evidence for altered tight junctions in carcinomas has been
known for more than 30 years [11]. Observations in examined
tumors include attenuation or lack of tight junctions, increased
paracellular permeability, and reductions in the number of
tight junction strands which all result in a decrease in the epi-
thelial barrier function of cells. Therefore, the loss of tight
junctions appears to constitute an essential step in cancer
development [11–14]. Tight junction proteins also play critical
roles in cellular proliferation and neoplastic pathways via their
functions as transmitters of the extracellular environment to
intracellular signaling pathways [15].
Claudins are a large family of essential tight junction pro-
teins [16]. There are two major functions deﬁned for claudins:
the regulation of paracellular permeability and maintenance of
the cell polarity [16].
The impact of claudin dysregulation deserves attention, as
it is now clear that these proteins play a role in tumorigenesis
and represent promising new targets for cancer diagnosis,
prognosis and therapy [17,18].
A multitude of studies reported down-regulation and up-
regulation of various claudins in various cancers [19]. How-
ever, only little information is available on the inﬂuence of
claudin expression on tumor behavior. Also, relatively few
studies have examined the role of claudins in the tumorigenesis
and prognosis of colonic carcinoma [20].So far, 24 members of the claudin family have been identi-
ﬁed [21]. Claudin-1 which is ubiquitously expressed in many
organs, is thought to be a universal marker of tight junctions
and is alleged to be associated with the development of various
cancers [22]. However, the signiﬁcance of claudin-1 expression
in cancer cells is not well understood [23]. In colonic carci-
noma, the molecular and morphological alterations of clau-
din-1 are still poorly understood [24–26].
The aim of this study was to detect caludin-1 expression in
colonic carcinoma and to correlate its expression with clinico-
pathological variables in an attempt to delineate its role as a
potential new prognostic marker.
Material and methods
Patients and tissue samples
The present work included 50 cases of colonic carcinomas that
were retrieved from the surgical pathology archives at the
Pathology Department, Faculty of Medicine, the Alexandria
University between the years 2004 and 2009. Complete clinical
data were available for all patients. None of these patients re-
ceived pre-operative adjuvant chemotherapy or radiotherapy.Pathological examination
Routinely processed parafﬁn-embedded tissues were cut into
5 lm-thick sections and stained with the conventional H&E
stain. Each case was carefully reviewed and graded according
to the WHO classiﬁcation system of gastrointestinal tumors
[27]. In addition, the stage of the tumor was established accord-
ing to the AJCC staging system [28].
Immunohistochemistry for claudin-1
Tissue sections (5 lm) were deparafﬁnized in xylene and rehy-
drated through graded ethanol to water. Hydrogen peroxide
was applied to block endogenous peroxidase activity. Antigen
retrieval was performed by boiling tissue sections in 10 mM
citrate buffer, pH 6.0. Slides were then incubated with the pri-
mary antibody (claudin-1, rabbit polyclonal antibody, ready to
use). The bound antibody was detected by the UltraVision
Detection System (Anti-Polyvalent, HRP/DAB, ready-
to-use). Both the primary antibody and the detection kit were
purchased from the Lab Vision Corporation (Neo Markers,
Fremont, USA). Immunohistochemical staining was per-
formed using an avidin–biotinylated immunoperoxidase meth-
odology. Both positive and negative controls were included in
all runs.
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Acasewas considered claudin-1 positive if any number of tumor
cells showed membranous and/or cytoplasmic positivity [19].
Both the intensity and the extent of claudin-1 immunostaining
were evaluated in tumor tissue as well as in the adjacent normal
mucosa which served as an internal control.
The intensity of staining was graded as either weak = 1;
moderate = 2; or strong = 3. The extent of staining was evalu-
ated semiquantitatively and categorized as focal (610%) = 1;
regional (11–50%) = 2; or diffuse (P50%) = 3.
Total scores for caludin-1 expression were then calculated
by multiplying the obtained scores of both intensity and extent
of staining [19].
Total scores of claudin-1 expression in the studied colonic
carcinoma cases were compared to the adjacent normal muco-
sa and a ﬁnal computed score for each case was calculated (by
subtraction of the total score in normal mucosa from the total
score in the tumor) [19].
In cases where total scores for claudin-1 expression in the tu-
morwere equal to the adjacent normalmucosa (ﬁnal score = 0),
the tumor was designated as having similar claudin-1 expression
to normal mucosa.
If the total score for claudin-1 expression in the tumor was less
than that in the normal mucosa (ﬁnal score less than 0), the tumor
was designated as having decreased claudin-1 expression.
If the total claudin-1 staining score in the tumor was higher
than the normal mucosa; (ﬁnal score more than 0), the tumor
was designated as having increased claudin-1 expression.
Statistical analysis
Datawere analyzed using PredictiveAnalytics Software (PASW
Statistics 18). Signiﬁcance of the obtained results was judged at
the 5% level.
Non-parametric tests such as the Wilcoxon Mann–Whitney
test, Kruskal–Wallis test, and Spearman’s rho correlation were
used.
Regression analysis was done. Linear models were devel-
oped aiming to identify the independent variable while control-
ling other variables.
The predictive performance of claudin-1 expression in colo-
nic carcinoma was evaluated using Receiver Operating Char-
acteristic (ROC) curve analysis. The cutoff point at which
the highest predictive accuracy was reached was estimated
using Youden Index.
Results
Clinicopathologic study
The age of the patients ranged from 17 to 75 years (mean: 52.6,
median: 53.5). 18 patients (36%) were males and 32 patients
(64%) were females with a M:F ratio of 1:1.8.
The most commonly involved part by the tumor was the ce-
cum (12 cases, 24%) followed by the ascending colon (10 cases,
20%), the sigmoid colon (nine cases, 18%), the descending co-
lon (seven cases, 14%), the transverse colon (six cases, 12%),
and the rectosigmoid area (six cases, 12%).
Microscopically, all cases were classiﬁed as adenocarci-
noma (NOS). Histological grading was done according to
the WHO grading system. Twenty-three cases (46%) were welldifferentiated, 18 cases (36%) were moderately differentiated
and nine cases (18%) were poorly differentiated.
The 50 cases included in this study were staged according to
AJCC staging system. The tumor invasion was limited to the
submucosa (T1) in only two cases (4%). Muscularis propria
invasion (T2) was noted in 15 cases (30%). In 31 cases
(62%) the tumor reached the subserosa (T3) while in two cases
(4%) the tumor directly invaded nearby organs or structures
(T4).
As regards lymph node metastasis, 33 cases (66%) were des-
ignated as N0 while seven cases (14%) were designated as N1
and 10 cases (20%) were designated as N2.
A total of 48 cases (96%) showed no distant metastasis
(M0), while only two cases (4%) showed distant metastasis
(M1) to the liver.
Finally, stage grouping was done and 14 cases (28%) were
stage I, 20 cases (40%) were stage II, 14 cases (28%)were stage
III, and two cases (4%) were stage IV.
Immunohistochemical study
Immunoreactivity was interpreted without prior knowledge of
any of the clinicopathologic parameters. Both the tumor and
adjacent normal colonic mucosa were separately scored for
claudin-1 expression.
The normal colonic mucosa showed diffuse claudin-1 stain-
ing with a strong intensity in all the studied cases. The staining
pattern was membranous with accentuation of the lateral rather
than apical borders. Cytoplasmic staining was also noted. The
total score for normal mucosa was nine in all of the studied
cases. No staining was observed in the stroma (Fig. 1a).
Claudin-1 expression in colonic adenocarcinomas (Fig. 1b–f)
was assessed regarding staining extent and intensity. The extent
of staining ranged from focal (eight cases, 16%) to regional (19
cases, 38%) to diffuse (23 cases, 46%). Staining intensity was
strong in 30 cases (60%),moderate in nine cases (18%) andweak
in 11 cases (22%). Total scores ranged from 1 to nine with a
mean of 5.84 ± 2.999.
The staining pattern was circumferential membranous and/
or cytoplasmic in well and moderately differentiated tumors.
An incomplete membranous pattern was focally noted in mod-
erately differentiated tumors. In poorly differentiated tumors,
the staining pattern was mainly cytoplasmic with minimal
incomplete membranous staining.
Claudin-1 expression in the studied colonic adenocarcinoma
caseswas similar to the normal colonicmucosa in 19 cases (38%)
and showed decreased expression in 31 cases (62%)where the ﬁ-
nal scores ranged from 3 to 8 (mean = 5.0968, med-
ian = 5). None of the studied colonic adenocarcinoma cases
showed increased claudin-1 expression.
Table 1 illustrates the distribution of claudin-1 expression
regarding tumor grade, depth of invasion, lymph node involve-
ment and tumor stage.
Relation between claudin-1 expression and clinicopathological
parameters (Table 2): statistical analysis showed that the relation be-
tween claudin-1 expression onone hand and age, sex and tumor loca-
tion on the other hand was insigniﬁcant (Spearman’s rho=0.093,
p=0.522, Mann–Whitney U=201.000, p=0.067, X2 = 8.490,
p=0.131 respectively).
Astatistically signiﬁcant strong inverse correlationwasdetected
between claudin-1 expressionononehandand tumorgrade, lymph
node status, and tumor stage in the other hand (Spearman’
Figure 1 Immunohistochemical expression of claudin-1. (a) Normal colonic mucosa showing diffuse membranous and cytoplasmic
claudin-1immunosatining of strong intensity (·100). (b) A case of well differentiated colonic adenocarcinoma showing similar claudin-1
expression (·40). (c) Higher power view of the previous case showing strong and diffuse circumferential membranous and cytoplasmic
claudin-1 immunostaining (·200). (d) A case of moderately differentiated colonic adenocarcinoma showing circumferential membranous
and cytoplasmic claudin-1 immunostaining. Incomplete membranous staining is noted (·400). (e) A case of poorly differentiated colonic
adenocarcinoma showing decreased claudin-1 expression (·40). (f) Higher power view of the previous case showing focal cytoplasmic
claudin-1 immunostaining of weak to moderate intensity (·400).
126 E. Abdelzaher et al.rho= 0.676, p< 0.000, Spearman’s rho= 0.592, p< 0.000,
and Spearman’s rho =0.640, p< 0.000 respectively). In addi-
tion, a statistically signiﬁcant, yet weak, inverse correlation was
found between claudin-1 expression and depth of tumor invasion
(Spearman’s rho= 0.280, p= 0.049) (Fig. 2).
Final score for claudin-1 expression in the two colonic carci-
noma cases associated with metastasis (mean=8, med-
ian =8) was lower than the ﬁnal claudin-1 score in cases not
associated with metastasis (mean =2.958, median =3).
However, statistical analysis could not be done due to small num-
ber of the cases.
Regression analysis and ROC curve analysis
The clinicopathological factors found to be signiﬁcantly corre-
lated with claudin-1 expression (the tumor grade, stage, depth
of tumor invasion and lymph node status) were subjected to
further regression statistical analysis. Three regression models
were generated to overcome the problem of multicollinearity
(Table 3).
From the developed models, claudin-1 decreased expression
was found to be a signiﬁcant independent predictor for tumorgrade, stage and lymph node status. Decreased claudin-1 expres-
sion signiﬁcantly predicts that the tumor is of a high grade, high
stage, and is associatedwith lymphnode involvement (p< 0.001,
p< 0.001, and p= 0.013 respectively).
A step further in analysis, ROC curve analysis was carried
out in order to detect a cut off value for claudin-1 expression
at which the highest predictive accuracy was reached. The
grade was omitted from the analysis since tumor grade can
be easily assessed histologically by light microscopic exami-
nation. A cutoff point was determined at ﬁnal score 5
(Fig. 3).
At the cutoff point of 5, claudin-1 showed a sensitivity of
88.24% and a speciﬁcity of 81.25% for the prediction of tumor
stage. The positive likelihood ratio was 4.71 and the negative like-
lihood ratio was 0.14. Predictive values were calculated with a po-
sitive predictive value of 90.9% and a negative predictive value of
76.5%. The predictive power was good (area under the
curve = 0.892, 95% CI= 0.772–0.962, p=<0.000).
As regards lymph node involvement, at the cutoff point of
5, claudin-1 showed a sensitivity of 73.33% and a speciﬁcity
of 82.86% for the prediction of lymph node status. The positive
Table 1 Distribution of claudin-1 expression.
Claudin-1 Similar expression Decreased expression
Number (%) Number (%)
Grade of the tumor WD 14 58.33 10 41.67
MD 5 29.41 12 70.59
PD 0 0 9 100
Tumor depth T1 0 0 2 100
T2 9 60 6 40
T3 9 29.03 22 70.97
T4 0 0 2 100
Lymph node involvement N0 18 54.55 15 45.45
N1 1 14.29 6 85.71
N2 0 0 10 100
Stage of the tumor I 10 71.43 4 28.57
II 9 45 11 55
III 0 0 12 100
IV 0 0 2 100
Table 2 Relation between claudin-1 expression and clinicopathologic parameters.
Claudin-1 ﬁnal score Min Max Mean SD Median Test p Value
Age <40 7.00 0.00 3.600 2.608 3.000 0.093a 0.522
40 8.00 0.00 2.077 3.095 0.000
50 8.00 0.00 3.375 3.202 3.000
60 8.00 0.00 4.250 2.864 3.000
70–75 5.00 0.00 2.000 2.450 1.500
Sex Male 8.00 0.00 4.167 2.936 4.000 Ub = 201.000 0.067
Female 8.00 0.00 2.594 2.928 3.000
Tumor site Cecum 8.00 0.00 2.250 3.166 0.000 (X2)c 8.490 0.131
Ascending colon 8.00 0.00 5.300 2.627 6.000
Transverse colon 7.00 0.00 3.333 3.141 3.000
Descending colon 8.00 0.00 3.143 3.579 3.000
Sigmoid colon 6.00 0.00 1.667 2.180 0.000
Rectosigmoid 7.00 0.00 3.500 2.345 3.000
Grade of the tumor WD 5.00 0.00 1.261 1.657 0.000 0.676a <0.000*
MD 8.00 0.00 3.611 2.790 3.000
PD 8.00 3.00 7.111 1.616 8.000
Tumor depth T1 7.00 0.00 3.500 4.950 3.500 0.280a 0.049*
T2 8.00 0.00 2.200 3.075 0.000
T3 8.00 0.00 3.290 2.723 3.000
T4 8.00 8.00 8.000 0.000 8.000
LN involvement N0 8.00 0.00 2.057 2.496 0.000 0.592a <0.000*
N1 6.00 0.00 3.800 2.388 5.000
N2 8.00 3.00 6.700 2.003 7.500
Metastasis M0 8.00 0.00 2.958 2.887 3.000 NAd NAd
M1 8. 00 8.00 8.000 0.000 8.000
Stage of the tumor I 7.00 0.00 1.429 2.593 0.000 0.640a <0.000*
II 8.00 0.00 2.100 2.359 3.000
III 8.00 3.00 5.714 1.857 5.500
IV 8.00 8.00 8.000 0.000 8.000
* Signiﬁcant value.
a Spearman’s rho correlation.
b Mann–Whitney test.
c Chi-square for Kruskal Wallis test.
d not applicable.
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0.32. Predictive values were calculated with a positive predictive
value of 64.7% and a negative predictive value of 87.9%. The
predictive power was good (area under the curve = 0.839,
95% CI = 0.708 to 0.927, p=<0.000).Discussion
Worldwide, every year more than one million individuals will
develop colonic carcinoma, and disease speciﬁc mortality rate
is nearly 33% in the developed world [29].
a b
c d
Figure 2 Scatter plot graphs: (a) a strong inverse correlation between claudin-1 expression and tumor grade. (b) A weak inverse correlation
between claudin-1 expression and tumor depth. (c) A strong inverse correlation between claudin-1 expression and lymph node involvement. (d) A
strong inverse correlation between claudin-1 expression and tumor stage.
128 E. Abdelzaher et al.Advances in molecular carcinogenesis, prognostic and pre-
dictive molecular markers have been recently developed
[1,30,31]. Among these markers are markers for tight junctions
[32]. The role of adherent junction proteins has been studied
extensively in cancer, but the roles of tight junction proteins
are less well understood [33]. Disruption of the cell–cell junc-
tion with concomitant changes in the expression of junctional
proteins is central to the cellular transformation and acquisi-
tion of metastatic potential [33].
Claudins are integral to the structure and function of tight
junctions [33]. Recent studies show changes in expression/cel-
lular localization of claudins during tumorigenesis; however,
a causal relationship between claudin expression/localization
and cancer has not been deﬁnitely established [26].
In the present study, 50 cases of colonic adenocarcinomas
were immunohistochemically studied for claudin-1 expression.
The nearby normal colonic mucosa was used as an internal
control and was also assessed for claudin-1 expression for
comparison. The extent, intensity and pattern of claudin-1
staining in normal colonic mucosa were similar to the resultsreported by other investigators [15,19] who reported that the
claudin-1 staining was cytoplasmic with accentuation of the
lateral cell membrane. In contrast Resnick et al. [15] reported
a circumferential claudin-1 immunostaining in the normal co-
lonic mucosa.
As regards the studied colonic adenocarcinoma cases, a
greater number of cases (31 cases, 62%) showed decreased
claudin-1 expression as compared to 19 cases (38%) that
showed similar claudin-1 expression to the normal colonic mu-
cosa. This result is in line with several previous studies re-
ported by Hahn-Stro¨mberg et al. [34] and Miwa et al. [35].
These authors reported a decreased claudin-1 expression in co-
lonic adenocarcinomas. Also Tokes et al. [36] reported a de-
creased claudin-1 expression in invasive breast carcinoma as
compared to the normal breast ducts.
The mechanisms underlying the decreased claudin-1 expres-
sion in colonic carcinoma remain unknown. It is not quite as
clear how down-regulation of claudins may contribute to the
neoplastic progression [20]. However, it has been proposed
that decreased expression of claudin-1 with the loss of cell
a b
Figure 3 ROC curve: (a) showing the predictive performance of claudin-1 for stage. (b) Showing the predictive performance of claudin-1
for lymph node status.
Table 3 Regression models.
Regression models Variable Test p Value VIFa
Preliminary model Grade F= 24.987 <0.001
Stage t= 2.803 0.008 4.093
Lymph node involvement t= 0.845 0.403 3.979
Tumor depth t= 1.257 0.216 1.126
(Constant) t= 2.282 0.027
R2 = 0.625. F= 17.363, p< 0.001
Model 1 Grade F= 24.987 0.000
Stage 4.724 0.000
(Constant) 2.060 0.045
R2 = 0.652. F= 31.650, p< 0.001
Model 2 Grade F= 24.987 <0.001
Lymph node involvement t= 2.730 0.009
(Constant) t= 2.597 0.013
R2 = 0.556, F= 21.428, p< 0.001
a VIF: variation inﬂation factor.
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factors, which give rise to auto- and paracrine stimulations of
neoplastic epithelia and thus provides nutrition factors and
other factors necessary for tumor cell growth [37,38]. Also, it
was proved that the injured structure and function of tight
junctions might disorder the cell proliferation and differentia-
tion and thus encourage the carcinogenesis [39].
A statistically signiﬁcant strong inverse correlation was
found between claudin-1 expression and the tumors’ grade in
the current study. These ﬁndings are in accordance with those
reported by Matsuoka et al. [40], Tzelepi et al. [41] and
Resnick et al. [15] who reported that decreased expression of
claudin-1 is signiﬁcantly associated with higher tumor grade
and poor differentiation. Moreover, Cha et al. [42] suggested
that claudin-1 expression may be correlated with the progres-
sion of colonic carcinoma.
In addition, Higashi et al. [22] reported that attenuated
expression of claudin-1 closely correlates with the dedifferen-
tiation of hepatocellular carcinoma and concluded thatdown-regulated claudin-1 expression may thus serve as a po-
tential marker for a poor prognosis in hepatocellular
carcinoma.
The results of our study together with other reports [18]
suggest that the decrease of claudin-1 expression in colonic
carcinoma of higher grade due to its down-regulation might
contribute to the more aggressive behavior of the tumors. This
could be explained by the fact that the preservation of cell
polarity and paracellular ﬂux by many claudin molecules sug-
gests that these proteins contribute to tumor suppressive func-
tions in epithelial neoplasia [43]. In addition, changes in or loss
of expression of tight junction proteins such as claudins can
lead to cellular disorientation and detachment, which are com-
monly seen in neoplasia [44].
In the present work, a statistically signiﬁcant inverse corre-
lation was found between claudin-1 expression and depth of
tumor invasion. This is in accordance with the ﬁndings re-
ported by Tokes et al. [36] who reported a decreased clau-
din-1 expression in invasive breast carcinoma.
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studied claudin-1 expression in lung carcinoma. They reported
that overexpression of claudin-1 suppressed cancer cell migra-
tion, invasion and metastasis. They thus concluded that clau-
din-1 is a cancer invasion and metastasis suppressor.
In contrast to our ﬁndings, Kingusa et al. [46], Leotlela et al.
[47] and others [35,38] reported overexpression of claudin-1 in
invasive tumor cells. They explained their ﬁndings by the fact
that claudins are able to interact with membrane-type matrix
metalloproteinases (MT-MMPs) and thus promote MMP
activity. They thus concluded that claudin overexpression
seems to be an early event in carcinogenesis at least for some
cancer types.
Also, in this study, a statistically signiﬁcant strong inverse cor-
relation was seen between claudin-1 expression and lymph node
involvement. Ersoz et al. [48] reported similar results and con-
cluded that claudin-1 expression in colonic carcinoma was signif-
icantly decreased with lymph node metastasis. These ﬁndings
were also in agreement with those reported by Cha et al. [42].
These ﬁndings were explained by the fact that a modiﬁca-
tion in the tight junction function and structure may affect tu-
mor penetration, [49] and that loss of claudins and other tight
junction proteins account for the loss of cell adhesion which is
an important step in the development of tumor invasion and
metastasis [50].
On the other hand, several authors reported an increase in
claudin-1 expression in metastatic carcinomas [26,45]. The rea-
son for the discrepancy observed in claudin expression among
the different tissues is unclear but may be related to tissue-
speciﬁc differences in claudin function or even in the tissue
microenvironmental factors [51]. The discrepancy could also
be explained by the differences in methodology and antibodies
used.
In the present study, claudin-1 expression was also corre-
lated with the tumor stage which is until now considered the
most important prognostic factor in colonic carcinoma [52].
A statistically signiﬁcant strong inverse correlation was found
between claudin-1 expression and tumor stage. These results
are in accordance with those reported by Matsuoka et al.
[40] who stated that a reduced expression of claudin-1 was cor-
related with advanced tumor stage.
Also, the results are in agreement with other recent studies
[20,35,53]. These studies highlighted the role that claudin-1
plays in invasion and metastasis and tumor progression. In
contrast, Gro¨ne et al. [54] showed no clear correlation between
claudin-1 expression and tumor stage.
In the present work, regression analysis showed that clau-
din-1 decreased expression was a signiﬁcant independent pre-
dictor for tumor grade, stage and lymph node status.
Decreased claudin-1 expression signiﬁcantly predicts that the
tumor is of a high grade, high stage, and is associated with
lymph node involvement.
An additional statistical test was done to delineate a cut off
point that signiﬁcantly discriminates between low and high
stage tumors as well as predicts lymph node status. A cutoff
point was determined at a ﬁnal score of 5.
At the cutoff point of 5, claudin-1 showed a sensitivity of
88.24% and a speciﬁcity of 81.25% for the prediction of tumor
stage as well as a sensitivity of 73.33% and a speciﬁcity of
82.86% for the prediction of lymph node status. The predictive
power was good.Accordingly, claudin-1 decreased expression with a ﬁnal
score of 65 signiﬁcantly predicts that the tumor is of high
stage (III or IV) and is associated with lymph node metastasis.
On the other hand, if claudin-1 ﬁnal score is > 5, it signiﬁ-
cantly predicts that the tumor is of low stage (I or II) and is
associated with negative lymph nodes.
Thus, the level of claudin-1 expression could predict the
stage and lymph node status of an individual patient. How-
ever, these results need to be supported by further studies on
a larger scale of patients.
From the present work it can be concluded that, claudin-1
is consistently expressed in non-neoplastic colonic mucosa
which emphasizes its important role in maintaining the normal
function and morphology of colonocytes. Claudin-1 may be
involved in the process of colonic tumorigenesis. Claudin-1 de-
creased expression contributes to the progression and dediffer-
entiation of colonic carcinoma and it may underlie the invasive
and metastatic potential of colonic carcinoma. Immunohisto-
chemical claudin-1 expression could be used as a predictor of
colonic carcinoma stage as well as lymph node status with a
high sensitivity and speciﬁcity.References
[1] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
2002. CA Cancer J Clin 2005;55(2):74.
[2] Parkin D, Ferlay J, Cherif HM, Sitas F, Thomas J, Wabinga H,
et al. Cancer in Africa: epidemiology and prevention. Lyon:
IARC Press International Agency for Research on Cancer
(IARC); 2003 [277–281].
[3] El-Bolkainy N, Nouh M, El-Bolkainy T. Topographic
pathology of cancer. 3rd ed. Cairo: Egyptian National Cancer
Institiute; 2005, p. 83.
[4] Arnold CN, Goel A, Blum HE, Richard Boland C. Molecular
pathogenesis of colonic cancer. Cancer 2005;104(10):2035–47.
[5] Rowley PT. Inherited susceptibility to colonic cancer. Annu Rev
Med 2005;56:539–54.
[6] KahlenbergMS, Sullivan JM,WitmerDD,PetrelliNJ.Molecular
prognostics in colonic cancer. Surg Oncol 2003;12(3):173–86.
[7] Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I,
Kerr D. Genetic prognostic and predictive markers in colonic
cancer. Nat Rev Cancer 2011;11(4):309.
[8] Kim MS, Lee J, Sidransky D. DNA methylation markers in
colonic cancer. Cancer Metast Rev 2010;29(1):181–206.
[9] Andreyev J, Cunningham D. Markers, markers everywhere.
Prognosis in colonic cancer-time for a new approach. J Clin
Oncol 2001;19(2):286.
[10] Gonza´lez-Mariscal L, Lechuga S, Garay E. Role of tight
junctions in cell proliferation and cancer. Prog Histochem
Cytochem 2007;42(1):1–57.
[11] Alrov J. Ultrastructure of canine urinary bladder carcinoma.
Vet Path Online 1979;16(6):693.
[12] Martinez-Palomo A. Ultrastructural modiﬁcations of
intercellular junctions in some epithelial tumors. Lab Invest
1970;22(6):605.
[13] Robenek H, Scho¨pper C, Fasske E, Fetting R, Themann H.
Structure and function of the junctional complement of
spontaneous and transplanted murine mammary carcinomas. J
Submicrosc Cytol 1981;13(3):347.
[14] Swift J, Mukherjee T, Rowland R. Intercellular junctions in
hepatocellular carcinoma. J Submicrosc Cytol 1983;15(3):799.
[15] Resnick M, Konkin T, Routhier J, Sabo E, Pricolo V. Claudin-1
is a strong prognostic indicator in stage II colonic cancer: a
tissue microarray study. Mod Pathol 2004;18(4):511–8.
Predictive value of immunohistochemical expression of claudin-1 in colonic carcinoma 131[16] Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight
junctions. Nat Rev Mol Cell Biol 2001;2(4):285–93.
[17] Morin PJ. Claudin proteins in human cancer: promising new
targets for diagnosis and therapy. Cancer Res 2005;65(21):9603.
[18] Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various
types of tumours. Histopathology 2005;46(5):551–60.
[19] Sheehan GM, Kallakury BVS, Sheehan CE, Fisher HAG,
Kaufman Jr RP, Ross JS. Loss of claudins-1 and -7 and
expression of claudins-3 and -4 correlate with prognostic variables
in prostatic adenocarcinomas. Hum Pathol 2007;38(4):564–9.
[20] Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE.
Claudin-1 is a strong prognostic indicator in stage II colonic
cancer: a tissue microarray study. Mod Pathol 2005;18(4):511–8.
[21] Forster C. Tight junctions and the modulation of barrier
function in disease. Histochem Cell Biol 2008;130(1):55–70.
[22] Higashi Y, Suzuki S, Sakaguchi T, Nakamura T, Baba S, Reinecker
HC, et al. Loss of claudin-1 expression correlates with malignancy
of hepatocellular carcinoma. J Surg Res 2007;139(1):68–76.
[23] Akasaka H, Sato F, Morohashi S, Wu Y, Liu Y, Kondo J, et al.
Anti-apoptotic effect of claudin-1 in tamoxifen-treated human
breast cancer MCF-7 cells. BMC Cancer 2010;10:548.
[24] HuoQ,KinugasaT,WangL,HuangJ,ZhaoJ, ShibaguchiH, et al..
Claudin-1 protein is a major factor involved in the tumorigenesis of
colonic cancer. Anticancer Res 2009;29(3):851–7.
[25] Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG,
et al. Claudin-1 has tumor suppressive activity and is a direct
target of RUNX3 in gastric epithelial cells. Gastroenterology
2010;138(1):255–65.
[26] Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C,
et al. Claudin-1 regulates cellular transformation and metastatic
behavior in colon cancer. J Clin Invest 2005;115(7):1765–76.
[27] Stanley R, Hamilton LA. Pathology and genetics of tumours of
the digestive system. Lyon: IARC Press International Agency
for Research on Cancer (IARC), 2000;105–119.
[28] Green F, Balch C, Fleming I, Fritz A, Haller D, Morrow M,
et al. AJCC cancer staging handbook. 6th edition. New
York: Springer; 2002, p. 176–186.
[29] Cunningham D. Colonic cancer reply. Lancet
2010;376(9738):331–2.
[30] Rudmik L, Magliocco A. Molecular mechanisms of hepatic
metastasis in colonic cancer. J Surg Oncol 2005;92(4):347–59.
[31] Compton C, Fenoglio Preiser CM, Pettigrew N, Fielding LP.
American joint committee on cancer prognostic factors
consensus conference. Cancer 2000;88(7):1739–57.
[32] Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan
AT, et al. Phosphorylated AKT expression is associated with
PIK3CA mutation, low stage, and favorable outcome in 717
colonic cancers. Cancer 2011;117(7):1399–408.
[33] Singh AB, Sharma A, Dhawan P. Claudin family of proteins
and cancer: an overview. J Oncol 2010;2010:11.
[34] Hahn-Stro¨mberg V, Edvardsson H, Bodin L, Franze´n L.
Claudin 1 and claudin 7 gene polymorphisms and protein
derangement are unrelated to the growth pattern and tumor
volume of colon carcinoma. Int J Biomed Sci 2010;6(2):96–102.
[35] Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y,
Furukawa Y. Involvement of claudin-1 in the beta-catenin Tcf
signaling pathway and its frequent upregulation in human
colonic cancers. Oncol Res Feat Preclin Clin Cancer Therap
2001;11(12):469–76.
[36] Tokes AM, Kulka J, Paku S, Szik A, Paska C, Novak PK, et al.
Claudin-1, -3 and -4 proteins and mRNA expression in benignand malignant breast lesions: a research study. Breast Cancer
Res 2005;7(2):296–305.
[37] Mullin JM. Potential interplay between luminal growth factors
and increased tight junction permeability in epithelial
carcinogenesis. J Exp Zool 1997;279(5):484–9.
[38] de Oliveira SS, de Oliveira IM, De Souza W, Morgado-Dı´az JA.
Claudins upregulation in human colonic cancer. FEBS Lett
2005;579(27):6179.
[39] Mitic L, Anderson J. Molecular architecture of tight junctions.
Annu Rev Physiol 1998;60(1):121–42.
[40] Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T,
Hayashi T, et al. Cluster analysis of claudin-1 and -4, E-
cadherin, and beta-catenin expression in colonic cancers. J Surg
Oncol 2011;103(7):674–86.
[41] Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa
CD. Tight junctions in thyroid carcinogenesis: diverse
expression of claudin-1, claudin-4, claudin-7 and occludin in
thyroid neoplasms. Mod Pathol 2008;21(1):22–30.
[42] Cha EJ, Jang KY, Choi HN, Kim KR, Choi KH,
Hwang SH, et al. Expression of claudin-1, beta-catenin and E-
cadherin in adenocarcinoma of the colon. Korean J Med
2008;74(2):146–53.
[43] Jakab C, Rusvai M, Galﬁ P, Szabo Z, Szabara A. Expression of
claudin-1, -3, -4, -5 and -7 proteins in low grade colonic
carcinoma of canines. Histol Histopathol 2010;25(1):55–62.
[44] French AD, Fiori JL, Camilli TC, Leotlela PD, O’Connell MP,
Frank BP, et al. PKC and PKA phosphorylation affect the
subcellular localization of claudin-1 in melanoma cells. Int J
Med Sci 2009;6(2):93–101.
[45] Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, et al.
Claudin-1 is a metastasis suppressor and correlates with clinical
outcome in lung adenocarcinoma. Am J Respir Crit Care Med
2008;179(2):123–33.
[46] Kinugasa T, Huo Q, Higashi D, Shibaguchi H, Kuroki M,
Tanaka T, et al. Selective up-regulation of claudin-1 and
claudin-2 in colonic cancer. Anticancer Res 2007;27(6A):3729.
[47] Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF,
Rosenthal DT, et al. Claudin-1 overexpression in melanoma is
regulated by PKC and contributes to melanoma cell motility.
Oncogene 2007;26(26):3846–56.
[48] Ersoz S, Mungan S, Cobanoglu U, Turgutalp H, Ozoran Y.
Prognostic importance of claudin-1 and claudin-4 expression in
colon carcinomas. Pathol Res Pract 2011;207(5):285–9.
[49] Jiang WG, Martin T, Llaffaﬁan I, Mansel RE. Tight junctions, a
critical structure in the control of cancer invasion and
metastasis. Cancer Metast Mol Cell Mech Clin Interv
2004:195–213.
[50] Swisshelm K, Macek R, Kubbies M. Role of claudins in
tumorigenesis. Adv Drug Deliv Rev 2005;57(6):919–28.
[51] Oliveira SS, Morgado-Dı´az JA. Claudins: multifunctional
players in epithelial tight junctions and their role in cancer.
Cell Mol Life Sci 2007;64(1):17–28.
[52] Kehoe J, Khatri VP. Staging and prognosis of colon cancer.
Surg Oncol Clin N Am 2006;15(1):129.
[53] Hoevel T, Macek R, Swisshelm K, Kubbies M. Reexpression of
the TJ protein CLDN1 induces apoptosis in breast tumor
spheroids. Int J Cancer 2004;108(3):374–83.
[54] Gro¨ne J, Weber B, Staub E, Heinze M, Klaman I, Pilarsky C,
et al.. Differential expression of genes encoding tight junction
proteins in colonic cancer: frequent dysregulation of claudin-1,-8
and-12. Int J Colon Dis 2007;22(6):651–9.
